ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 167,50
-0,26%
Dow Jones
39 892,01
0,06%
DAX
18 704,42
-0,11%
Brent Oil
83,39
0,22%
Bitcoin
67 129,42
2,90%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Atea Pharmaceuticals Inc (AVIR)

  7. Atea Pharmaceuticals Inc (AVIR) Actualités

AVIR

Atea Pharmaceuticals (AVIR)

Atea Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AVIR
DateHeureSourceTitreSymboleSociété
14/05/202422h43Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AVIRAtea Pharmaceuticals Inc
14/05/202422h16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVIRAtea Pharmaceuticals Inc
14/05/202422h05GlobeNewswire Inc.Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
07/05/202413h00GlobeNewswire Inc.Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
29/04/202413h00GlobeNewswire Inc.Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
27/03/202412h00GlobeNewswire Inc.Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk PatientsNASDAQ:AVIRAtea Pharmaceuticals Inc
28/02/202422h05GlobeNewswire Inc.Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
21/02/202413h00GlobeNewswire Inc.Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
03/02/202403h29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVIRAtea Pharmaceuticals Inc
01/02/202422h15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AVIRAtea Pharmaceuticals Inc
08/01/202422h05GlobeNewswire Inc.Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19NASDAQ:AVIRAtea Pharmaceuticals Inc
03/01/202413h00GlobeNewswire Inc.Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:AVIRAtea Pharmaceuticals Inc
13/11/202313h00GlobeNewswire Inc.Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023NASDAQ:AVIRAtea Pharmaceuticals Inc
08/11/202322h05GlobeNewswire Inc.Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
08/11/202313h00GlobeNewswire Inc.Atea Pharmaceuticals Announces Participation at Upcoming Investor ConferencesNASDAQ:AVIRAtea Pharmaceuticals Inc
02/11/202312h00GlobeNewswire Inc.Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023NASDAQ:AVIRAtea Pharmaceuticals Inc
01/11/202312h00GlobeNewswire Inc.Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023NASDAQ:AVIRAtea Pharmaceuticals Inc
06/09/202313h00GlobeNewswire Inc.Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare ConferenceNASDAQ:AVIRAtea Pharmaceuticals Inc
08/08/202322h05GlobeNewswire Inc.Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
01/08/202313h00GlobeNewswire Inc.Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023NASDAQ:AVIRAtea Pharmaceuticals Inc
21/06/202322h06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AVIRAtea Pharmaceuticals Inc
15/06/202313h00GlobeNewswire Inc.Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir CombinationNASDAQ:AVIRAtea Pharmaceuticals Inc
12/06/202314h20Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:AVIRAtea Pharmaceuticals Inc
05/06/202322h20GlobeNewswire Inc.Atea Pharmaceuticals to Present at the Jefferies Healthcare ConferenceNASDAQ:AVIRAtea Pharmaceuticals Inc
30/05/202313h00GlobeNewswire Inc.Atea Pharmaceuticals’ Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra BiosciencesNASDAQ:AVIRAtea Pharmaceuticals Inc
23/05/202322h05GlobeNewswire Inc.Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra BiosciencesNASDAQ:AVIRAtea Pharmaceuticals Inc
08/05/202322h16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AVIRAtea Pharmaceuticals Inc
08/05/202322h05GlobeNewswire Inc.Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
01/05/202322h05GlobeNewswire Inc.Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023NASDAQ:AVIRAtea Pharmaceuticals Inc
28/04/202322h10Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:AVIRAtea Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:AVIR

Dernières Valeurs Consultées

LSE
LION
NYSE
CMA
Comerica
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés